Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E S G Stroes

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|July 19, 2021
Working towards full eradication of lipid-driven cardiovascular risk?N S Nurmohamed, E S G Stroes
The Netherlands Journal of Medicine|May 29, 2013
Antisense oligonucleotides in the treatment of lipid disorders: pitfalls and promisesJ Besseling, G K Hovingh, E S G Stroes
The Netherlands Journal of Medicine|September 22, 2009
Where the immune response meets the vessel wallR J Bisoendial, E S G Stroes, P P Tak
Current Pharmaceutical Design|January 16, 2013
The promise of cholesteryl ester transfer protein (CETP) inhibition in the treatment of cardiovascular diseaseA E Bochem, J A Kuivenhoven, E S G Stroes
Nederlands Tijdschrift Voor Geneeskunde|November 17, 2020
[Anti-inflammatory therapy in cardiovascular disease; from hypothesis to future guideline?]R M Hoogeveen, E S G Stroes, J H Cornel
Current Pharmaceutical Design|January 14, 2011
Critical determinants of cardiovascular risk in rheumatoid arthritisR J Bisoendial, E S G Stroes, P P Tak
Diabetes, Obesity & Metabolism|October 11, 2007
Normalization of metabolic syndrome using fenofibrate, metformin or their combinationM Nieuwdorp, E S G Stroes, J J P Kastelein, et al.
Expert Review of Cardiovascular Therapy|June 9, 2020
Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemiaN S Nurmohamed, G M Dallinga-Thie, E S G Stroes
The Netherlands Journal of Medicine|November 13, 2013
Intestinal cholesterol secretion: future clinical implicationsL Jakulj, J Besseling, E S G Stroes, et al.
Diabetes, Obesity & Metabolism|June 4, 2008
Combination statin-fibrate therapy: safety aspectsR Franssen, M Vergeer, E S G Stroes, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|July 19, 2021
Working towards full eradication of lipid-driven cardiovascular risk?N S Nurmohamed, E S G Stroes
The Netherlands Journal of Medicine|May 29, 2013
Antisense oligonucleotides in the treatment of lipid disorders: pitfalls and promisesJ Besseling, G K Hovingh, E S G Stroes
The Netherlands Journal of Medicine|September 22, 2009
Where the immune response meets the vessel wallR J Bisoendial, E S G Stroes, P P Tak
Current Pharmaceutical Design|January 16, 2013
The promise of cholesteryl ester transfer protein (CETP) inhibition in the treatment of cardiovascular diseaseA E Bochem, J A Kuivenhoven, E S G Stroes
Nederlands Tijdschrift Voor Geneeskunde|November 17, 2020
[Anti-inflammatory therapy in cardiovascular disease; from hypothesis to future guideline?]R M Hoogeveen, E S G Stroes, J H Cornel
Current Pharmaceutical Design|January 14, 2011
Critical determinants of cardiovascular risk in rheumatoid arthritisR J Bisoendial, E S G Stroes, P P Tak
Diabetes, Obesity & Metabolism|October 11, 2007
Normalization of metabolic syndrome using fenofibrate, metformin or their combinationM Nieuwdorp, E S G Stroes, J J P Kastelein, et al.
Expert Review of Cardiovascular Therapy|June 9, 2020
Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemiaN S Nurmohamed, G M Dallinga-Thie, E S G Stroes
The Netherlands Journal of Medicine|November 13, 2013
Intestinal cholesterol secretion: future clinical implicationsL Jakulj, J Besseling, E S G Stroes, et al.
Diabetes, Obesity & Metabolism|June 4, 2008
Combination statin-fibrate therapy: safety aspectsR Franssen, M Vergeer, E S G Stroes, et al.
Pageof 4